BriaCell Therapeutics Stock Price

0.12 (2.7%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
BriaCell Therapeutics Corporation BCTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.12 2.7% 4.57 13:45:27
Open Price Low Price High Price Close Price Prev Close
4.40 4.40 4.89 4.45
Bid Price Ask Price Spread News
4.57 4.62 0.05 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,577 515,801 $ 4.68 $ 2,415,663 - 2.8149 - 9.00
Last Trade Time Type Quantity Stock Price Currency
13:46:21 2 $ 4.595 USD


Draw Mode:

BriaCell Therapeutics Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 69.51M 15.21M 15.21M $ - $ - - -4.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

BriaCell Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BCTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.764.894.254.50684,898-0.19-3.99%
1 Month5.506.804.255.402,043,760-0.93-16.91%
3 Months3.909.002.825.934,441,3770.6717.18%
6 Months4.249.002.81495.533,015,9850.337.78%
1 Year4.249.002.81495.533,015,9850.337.78%
3 Years4.249.002.81495.533,015,9850.337.78%
5 Years4.249.002.81495.533,015,9850.337.78%

BriaCell Therapeutics Description

BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.

Your Recent History
BriaCell T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.